Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – St. Croix Website

Brad St. Croix, Ph.D.

Selected Publications

1)  Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, Logsdon D, Morris H, Swing DA, Patel NL, Kalen J, Haines DC, Zudaire E, St Croix B.
COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models.
Sci Transl Med. 6: 242ra84, 2014.
[Journal]
2)  Kuo F, Histed S, Xu B, Bhadrasetty V, Szajek LP, Williams MR, Wong K, Wu H, Lane K, Coble V, Vasalatiy O, Griffiths GL, Paik CH, Elbuluk O, Szot C, Chaudhary A, St Croix B, Choyke P, Jagoda EM.
Immuno-PET Imaging of Tumor Endothelial Marker 8 (TEM8).
Mol. Pharm. 2014.
[Journal]
3)  Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M.
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Mol. Cancer Ther. 12: 416-26, 2013.
[Journal]
4)  Yang MY, Hilton MB, Seaman S, Haines DC, Nagashima K, Burks CM, Tessarollo L, Ivanova PT, Brown HA, Umstead TM, Floros J, Chroneos ZC, St Croix B.
Essential regulation of lung surfactant homeostasis by the orphan G protein-coupled receptor GPR116.
Cell Rep. 3: 1457-64, 2013.
[Journal]
5)  Stránecký V, Hoischen A, Hartmannová H, Zaki MS, Chaudhary A, Zudaire E, Nosková L, Barešová V.
Mutations in ANTXR1 Cause GAPO Syndrome.
Am. J. Hum. Genet. 92: 792-9, 2013.
[Journal]
6)  Chaudhary A, St Croix B.
Selective blockade of tumor angiogenesis.
Cell Cycle. 11: 2253-9, 2012.
[Journal]
7)  Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, Tschantz WR, Zhang XM, Saha S, Fleming T, St Croix B.
TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types.
Cancer Cell. 21: 212-26, 2012.
[Journal]
8)  Langenkamp E, Zwiers PJ, Moorlag HE, Leenders WP, St Croix B, Molema G.
Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Anticancer Drugs. 23: 161-72, 2012.
[Journal]
9)  Meehan B, Appu S, St Croix B, Rak-Poznanska K, Klotz L, Rak J.
Age-related properties of the tumour vasculature in renal cell carcinoma.
BJU Int. 107: 416-24, 2011.
[Journal]
10)  Cullen M, Elzarrad MK, Seaman S, Zudaire E, Stevens J, Yang MY, Li X, Chaudhary A, Xu L, Hilton MB, Logsdon D, Hsiao E, Stein EV, Cuttitta F, Haines DC, Nagashima K, Tessarollo L, St Croix B.
GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier.
Proc. Natl. Acad. Sci. U.S.A. 108: 5759-64, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 7/21/2014.